ABT - Abbott Laboratories
| Previous Close | 76.03 |
| Open | 76.14 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1800 |
| Day's Range | 75.85 - 76.59 |
| 52 Week Range | 60.32 - 80.74 |
| Volume | 2,995,203 |
| Avg. Volume | 5,483,753 |
| Market Cap | 134.536B |
| Beta (3Y Monthly) | 0.83 |
| PE Ratio (TTM) | 51.74 |
| EPS (TTM) | 1.47 |
| Earnings Date | Jul 16, 2019 - Jul 22, 2019 |
| Forward Dividend & Yield | 1.28 (1.61%) |
| Ex-Dividend Date | 2019-04-12 |
| 1y Target Est | 83.06 |
- Motley Fool•14 hours ago
3 Dividend Aristocrats to Buy and Hold Forever
Stable businesses that dole out a regular paycheck are like a warm blankie for your portfolio.
- Investopedia•yesterday
The World's Top 10 Health Care Companies (UNH, MDT)
Discover the world's top 10 health care companies according to market capitalization, including a brief summary of each.
- PR Newswire•2 days ago
TRILUMINATE Study Shows Treatment with Abbott's First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks
- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR - Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation ...
- Simply Wall St.•5 days ago
Should Abbott Laboratories (NYSE:ABT) Be Part Of Your Dividend Portfolio?
Is Abbott Laboratories (NYSE:ABT) a good dividend stock? How would you know? Dividend paying companies with growing...
- Investopedia•6 days ago
Most Important Mergers and Acquisitions of 2016
While 2016 did not see a $100 billion deal, there were plenty of important multibillion-dollar deals.
- Zacks•6 days ago
Why Is Abbott (ABT) Up 3.6% Since Last Earnings Report?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire•7 days ago
New ZonePerfect® Keto is 100% #TrueKeto with the Proven Blend of Macros for Effective Results
ABBOTT PARK, Ill., May 16, 2019 /PRNewswire/ -- You don't need to follow #TransformationTuesday on Instagram or read the latest pop culture magazine to know that nearly half of Americans are trying to lose weight.1 The ketogenic or "keto" diet – a high fat, moderate protein and very low carbohydrate eating pattern – is proven to be an effective weight management plan when followed correctly,2 yet not all keto products on the market have the right ratio of macronutrients ("macros") to yield the best results. To address this need, Abbott (ABT) is launching new ZonePerfect® Keto made with 75% fat, 20% protein and 5% carbs.
- PR Newswire•8 days ago
Nearly 9 out of 10 College Students with Student Debt Say It's Important to Find a Company That Offers Loan Relief
ABBOTT PARK, Ill., May 15, 2019 /PRNewswire/ -- Student loan debt – affecting 1 in 4 Americans and topping $1.5 trillion – is one of the most pressing concerns of students graduating college this spring. Nearly 70% of graduates today have taken out a loan – and a recent survey of college students shows that 9 out of 10 of them are on the hunt for a company with a student loan perk.
- MarketWatch•9 days ago
Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman
As uncertainty over the outcome of Sino-American trade talks grows, so does the possibility of a longer-than-expected negotiations or an all-out trade war, strategists at Goldman Sachs are providing some timely trading strategies.
- PR Newswire•9 days ago
Abbott Partners With NIH On BRAIN Initiative to Advance Research for Neurological Disorders
ABBOTT PARK, Ill., May 14, 2019 /PRNewswire/ -- Abbott (ABT) today announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neuroscience research. As part of the agreement, Abbott will provide the company's neuromodulation technologies—including directional deep brain stimulation (DBS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) therapy—for research related to these NIH initiatives to explore their application for chronic pain and progressive movement disorders, like Parkinson's disease.
- Zacks•10 days ago
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
- Zacks•13 days ago
Abbott (ABT) Upgraded to Buy: What Does It Mean for the Stock?
Abbott (ABT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•14 days ago
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes
- Zacks•14 days ago
Top Stock Reports for Verizon, Abbott & Illinois Tool Works
Top Stock Reports for Verizon, Abbott & Illinois Tool Works
- Zacks•15 days ago
Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up
A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results
- Zacks•15 days ago
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
- Reuters•15 days ago
Nestle, rivals vie for big baby formula prize in China's smaller cities
LONDON/BEIJING, May 7 (Reuters) - Nestle plans to launch a new line of baby formula in China this year under an existing brand, targeted at smaller cities, as the world's largest packaged food company tries to lengthen its lead in the world's biggest baby milk market. The new line, discussed exclusively with Reuters, will focus on smaller provincial cities, often in China's western provinces, where greater shipping distances and lower incomes can make some imported brand goods unaffordable, though wealth there is growing. Producers of many consumer staples such as soft drinks and soap had to seek growth in the less-profitable provincial cities years ago, as China's richer eastern markets matured.
- Zacks•15 days ago
Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates
Henry Schein's (HSIC) strong share gains in the North American market raise optimism.
- Investing.com•16 days ago
Abbott Labs Falls 3%
Investing.com - Abbott Labs (NYSE:ABT) fell by 3.10% to trade at $76.66 by 13:04 (17:04 GMT) on Tuesday on the NYSE exchange.
- PR Newswire•16 days ago
Abbott to Present at UBS Global Healthcare Conference
ABBOTT PARK, Ill., May 7, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Brian Yoor , executive vice president of finance and chief ...
- Zacks•16 days ago
Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top
Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.
- Zacks•16 days ago
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
- Zacks•16 days ago
Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid
Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.
- CNBC Videos•9 days ago
Is Pinterest a compelling buy? Is Abbott heading to new highs? The desk answers viewer questions
The "Halftime Report" traders answer viewer questions on Abbott Labs, Pinterest, Chevron, and Intel.
